US5165441032 - Common Stock - After market: 80.15 0 (0%)
NASDAQ:LNTH (3/28/2023, 7:00:00 PM)-0.32 (-0.4%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 698 full-time employees. The company went IPO on 2015-06-25. The firm classify its commercial products in three categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Its products in its precision diagnostics category includes DEFINITY, TechneLite, NEUROLITE, Xenon-133, Cardiolite, Gallium-67 and Thallium-201. Its products in its radiopharmaceutical oncology category includes PYLARIFY and AZEDRA. Its products in its strategic partnerships and other revenue product category includes RELISTOR, Automated Bone Scan Index (aBSI) and PYLARIFY AI. In addition to its commercial products and strategic partnerships with third parties, it also has ongoing clinical development programs, such as 1095 and LMI 1195. Its products are sold in both the United States and internationally.
LANTHEUS HOLDINGS INC
331 Treble Cove Rd
North Billerica MASSACHUSETTS 01862
CEO: Mary Anne Heino
Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer
Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer...
Current trends and changing demographics are behind growth of medical technology companies. An aging population and a shift to in-home care are among factors.
JMP Securities has initiated Lantheus Holdings (LNTH) with a market outperform rating saying the radiopharmaceuticals-focused company has "morphed into a MedTech growth leader...
The company's fourth-quarter and full-year earnings were a pleasant surprise.
LCID dropped on earnings news, dragging down the EV sector. W fell after its quarterly update. The release of financial figures prompted gains in LNTH and FIX.
Here you can normally see the latest stock twits on LNTH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.